Pharma struggles to adapt as patents expire
New threats to drug makers' revenues are rising even as the industry maneuvers to plug huge holes from looming patent expirations. A newly elected U.S. administration under President-elect Barack Obama brings concerns over pricing and further potential scrutiny, at a time when drug companies have already faced increased uncertainty from the regulators of their products. [more...]
|
|
|
